Axicabtagene Ciloleucel | Blood Cancers Today

axicabtagene ciloleucel

Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...

The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...

Cecilia BrownAggressive B-Cell Lymphoma | November 22, 2022

Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...

Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...

Kerri FitzgeraldAggressive B-Cell Lymphoma | November 14, 2022

The primary analysis of the study was published in Nature Medicine by Sattva S. Neelapu, MD.